Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://teniesonline.gr/
Are you over 18 and want to see adult content?
A complete backup of https://www.propertyturkey.com/real_estate/turkey
Are you over 18 and want to see adult content?
A complete backup of https://www.kurtvip.com/gurbetci-nurten/
Are you over 18 and want to see adult content?
A complete backup of https://www.digitria.in/maharashtra-ration-card/
Are you over 18 and want to see adult content?
A complete backup of https://slotsfree.com/
Are you over 18 and want to see adult content?
A complete backup of https://fb.allsmo.com/auto-follower
Are you over 18 and want to see adult content?
A complete backup of https://www.6to23.com/xmovies-for-u/
Are you over 18 and want to see adult content?
A complete backup of https://teniesonline.gr/seires/?m=&t=-1%20OR%203+593-
Are you over 18 and want to see adult content?
A complete backup of https://minuet.biz/ukraine/kiev/7452/ua/
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of celebritytalent.net
Are you over 18 and want to see adult content?
A complete backup of watch-putlocker-season-3-insecure-hbo.over-blog.com
Are you over 18 and want to see adult content?
A complete backup of info-alberghi.com
Are you over 18 and want to see adult content?
A complete backup of sweetlifeofa.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of adamantbarbell.com
Are you over 18 and want to see adult content?
A complete backup of conhecimentoeconomico.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of streetcontxt.com
Are you over 18 and want to see adult content?
Text
THERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 THERATECHNOLOGIES RESPONSES TO CURRENT COVID-19 PANDEMIC Ensuring patient access and product supply: Theratechnologies Inc. has enough inventory to provide TROGARZO®, EGRIFTA SVTM or EGRIFTA® to existing and new patients for the next 12 months. Production of TROGARZO®, EGRIFTA SVTM or EGRIFTA® has not been affected by the COVID-19 situation. The Department of Health and Human Services (DHHS) issued on Friday March Lire la suite CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
TH1904 - THERA
TH1904. Further preclinical research activities are being conducted using TH1904, our second investigational PDC (doxorubicin conjugate). In vitro and in vivo experiments using TH1904 have demonstrated results similar to those obtained with TH1902 and support the development of additional investigational compounds using our SORT1+ Technology™ that may help in the fight against cancer. THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
JOB DESCRIPTION MEDICINAL CHEMIST JOB DESCRIPTION . Medicinal Chemist . Department . Research and Development (R&D) Direct Supervisor . Manager, Chemistry . Team Management . N/A . Summary of PositionTHERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 THERATECHNOLOGIES RESPONSES TO CURRENT COVID-19 PANDEMIC Ensuring patient access and product supply: Theratechnologies Inc. has enough inventory to provide TROGARZO®, EGRIFTA SVTM or EGRIFTA® to existing and new patients for the next 12 months. Production of TROGARZO®, EGRIFTA SVTM or EGRIFTA® has not been affected by the COVID-19 situation. The Department of Health and Human Services (DHHS) issued on Friday March Lire la suite CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
TH1904 - THERA
TH1904. Further preclinical research activities are being conducted using TH1904, our second investigational PDC (doxorubicin conjugate). In vitro and in vivo experiments using TH1904 have demonstrated results similar to those obtained with TH1902 and support the development of additional investigational compounds using our SORT1+ Technology™ that may help in the fight against cancer. THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
JOB DESCRIPTION MEDICINAL CHEMIST JOB DESCRIPTION . Medicinal Chemist . Department . Research and Development (R&D) Direct Supervisor . Manager, Chemistry . Team Management . N/A . Summary of Position NEWS ABOUT THERATECHNOLOGIES Theratechnologies Announces Results from Two Posters Presented at ACTHIV2021 Annual Meeting Highlighting Positive Patient Experience with Trogarzo®. May 18, 2021. Theratechnologies To Participate in Virtual Fireside Chat With Canaccord Genuity On May 20, 2021. May 13,2021.
CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 THERATECHNOLOGIES TO HOST KEY OPINION LEADER EVENT TO – Webinar on Monday, June 21, 2021 at 11:00 a.m. ET – Montreal, Canada – June 10, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will host a key opinion leader (KOL) webinar on the Company’s SORT1+ Technology™ Lire la suite THERATECHNOLOGIES RESPONSES TO CURRENT COVID-19 PANDEMIC Ensuring patient access and product supply: Theratechnologies Inc. has enough inventory to provide TROGARZO®, EGRIFTA SVTM or EGRIFTA® to existing and new patients for the next 12 months. Production of TROGARZO®, EGRIFTA SVTM or EGRIFTA® has not been affected by the COVID-19 situation. The Department of Health and Human Services (DHHS) issued on Friday March Lire la suite CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite VIRTUAL ANNUAL GENERAL MEETING GUIDELINES Virtual Annual Meeting of Shareholders, Montreal, Canada Date and Time: Thursday, May 13, 2021, at 10:00 a.m. Webcast: https://web.lumiagm.com/287439840 Download THERATECHNOLOGIES TO HOST KEY OPINION LEADER EVENT … 1 theratechnologies to host key opinion leader event to discuss its sort1+ technology™ for the treatment of all sortilin-expressing cancers - webinar on monday, june 21, 2021 at 11:00 a.m. et -THERATECHNOLOGIES
Montreal, Canada – March 24, 2021 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors. ANNOUNCEMENTS THERATECHNOLOGIES ANNUAL MEETING … 1 . ANNOUNCEMENTS . IN CONJUNCTION WITH THERATECHNOLOGIES ANNUAL MEETING . Montreal, Canada – May 13, 2021 - Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the MEMBERS OF THERATECHNOLOGIES MANAGEMENT Ms.Marie-Noël Colussi is a graduate of Université du Québec à Montréal in business administration. Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a major accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in R&D.THERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. THERATECHNOLOGIES TO HOST KEY OPINION LEADER EVENT … 1 theratechnologies to host key opinion leader event to discuss its sort1+ technology™ for the treatment of all sortilin-expressing cancers - webinar on monday, june 21, 2021 at 11:00 a.m. et - LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO … 1 . THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO SUPPORT ITS COMMERCIAL AND PIPELINE ASSETS . Montreal, Canada March – 29, 2021 – Theratechnologies Inc. (. Theratechnologies, or THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
JOB DESCRIPTION MEDICINAL CHEMIST JOB DESCRIPTION . Medicinal Chemist . Department . Research and Development (R&D) Direct Supervisor . Manager, Chemistry . Team Management . N/A . Summary of Position LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
THERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. THERATECHNOLOGIES TO HOST KEY OPINION LEADER EVENT … 1 theratechnologies to host key opinion leader event to discuss its sort1+ technology™ for the treatment of all sortilin-expressing cancers - webinar on monday, june 21, 2021 at 11:00 a.m. et - LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO … 1 . THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO SUPPORT ITS COMMERCIAL AND PIPELINE ASSETS . Montreal, Canada March – 29, 2021 – Theratechnologies Inc. (. Theratechnologies, or THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
JOB DESCRIPTION MEDICINAL CHEMIST JOB DESCRIPTION . Medicinal Chemist . Department . Research and Development (R&D) Direct Supervisor . Manager, Chemistry . Team Management . N/A . Summary of Position LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 THE JOBS AVAILABLE NOW AT THERATECHNOLOGIES Jobs available. Send your application to cv@theratech.com. Executive Assistant. Posted on 19 May 2021. Position summary. The incumbent supports the vice presidents (Legal Affairs and Finance departments) in the success of their mandates by handling the administrative and some of the legal aspects of their functions. PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES There are many products referenced at Theratechnologies that you can find here depending on their stage of development. ANNOUNCEMENTS THERATECHNOLOGIES ANNUAL MEETING … 1 . ANNOUNCEMENTS . IN CONJUNCTION WITH THERATECHNOLOGIES ANNUAL MEETING . Montreal, Canada – May 13, 2021 - Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite THERATECHNOLOGIES TO HOST KEY OPINION LEADER EVENT … 1 theratechnologies to host key opinion leader event to discuss its sort1+ technology™ for the treatment of all sortilin-expressing cancers - webinar on monday, june 21, 2021 at 11:00 a.m. et - LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
VIRTUAL AGM USER GUIDE Getting Started. This year’s annual meeting will be held virtually. You can participate online using your smartphone, tablet or computer. By participating online, you will be able to listen to a live audio - INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targetedTHERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO … 1 . THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO SUPPORT ITS COMMERCIAL AND PIPELINE ASSETS . Montreal, Canada March – 29, 2021 – Theratechnologies Inc. (. Theratechnologies, or - INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targeted THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH 1 406-01-02/18 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzoâ„¢ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not requireTHERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. JOB DESCRIPTION MEDICINAL CHEMIST JOB DESCRIPTION . Medicinal Chemist . Department . Research and Development (R&D) Direct Supervisor . Manager, Chemistry . Team Management . N/A . Summary of Position AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO … 1 . THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO SUPPORT ITS COMMERCIAL AND PIPELINE ASSETS . Montreal, Canada March – 29, 2021 – Theratechnologies Inc. (. Theratechnologies, or THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
- INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targeted PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES There are many products referenced at Theratechnologies that you can find here depending on their stage of development. THE JOBS AVAILABLE NOW AT THERATECHNOLOGIES Jobs available. Send your application to cv@theratech.com. Executive Assistant. Posted on 19 May 2021. Position summary. The incumbent supports the vice presidents (Legal Affairs and Finance departments) in the success of their mandates by handling the administrative and some of the legal aspects of their functions. ANNOUNCEMENTS THERATECHNOLOGIES ANNUAL MEETING … 1 . ANNOUNCEMENTS . IN CONJUNCTION WITH THERATECHNOLOGIES ANNUAL MEETING . Montreal, Canada – May 13, 2021 - Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
GLOBAL NEW PRODUCT PLANNING JOB DESCRIPTION GLOBAL NEW PRODUCT PLANNING Service Commercial Direct Supervisor Global Commercial Officer Management of Team N/A Position Summary This role is an integral part of the Commercial Leadership Team and works closely with the VIRTUAL AGM USER GUIDE Getting Started. This year’s annual meeting will be held virtually. You can participate online using your smartphone, tablet or computer. By participating online, you will be able to listen to a live audio THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH 1 406-01-02/18 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not require - INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targetedTHERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO … 1 . THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO SUPPORT ITS COMMERCIAL AND PIPELINE ASSETS . Montreal, Canada March – 29, 2021 – Theratechnologies Inc. (. Theratechnologies, or - INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targeted THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH 1 406-01-02/18 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzoâ„¢ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not requireTHERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO … 1 . THERATECHNOLOGIES ANNOUNCES TWO STRATEGIC HIRES TO SUPPORT ITS COMMERCIAL AND PIPELINE ASSETS . Montreal, Canada March – 29, 2021 – Theratechnologies Inc. (. Theratechnologies, or - INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targeted THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH 1 406-01-02/18 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not require PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES There are many products referenced at Theratechnologies that you can find here depending on their stage of development. THE JOBS AVAILABLE NOW AT THERATECHNOLOGIES Jobs available. Send your application to cv@theratech.com. Executive Assistant. Posted on 19 May 2021. Position summary. The incumbent supports the vice presidents (Legal Affairs and Finance departments) in the success of their mandates by handling the administrative and some of the legal aspects of their functions. ANNOUNCEMENTS THERATECHNOLOGIES ANNUAL MEETING … 1 . ANNOUNCEMENTS . IN CONJUNCTION WITH THERATECHNOLOGIES ANNUAL MEETING . Montreal, Canada – May 13, 2021 - Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite LES EMPLOIS DISPONIBLES MAINTENANT CHEZ …TRANSLATE THIS PAGE Theratechnologies est constamment à la recherche de personnes talentueuses, énergiques et qui partagent les valeurs de l’entreprise. Si vous avez le goût de vous joindre à une équipe exceptionnelle et à un milieu de travail dynamique, respectueux et où les défis sont toujours présents, nous vous invitons à nous faire parvenir votre curriculum vitae. LA COMPAGNIE BIOPHARMACEUTIQUE THERATECHNOLOGIESTRANSLATE THIS PAGE Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
GLOBAL NEW PRODUCT PLANNING JOB DESCRIPTION GLOBAL NEW PRODUCT PLANNING Service Commercial Direct Supervisor Global Commercial Officer Management of Team N/A Position Summary This role is an integral part of the Commercial Leadership Team and works closely with the VIRTUAL AGM USER GUIDE Getting Started. This year’s annual meeting will be held virtually. You can participate online using your smartphone, tablet or computer. By participating online, you will be able to listen to a live audio THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH 1 406-01-02/18 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not require - INCREASING POTENCY OF ANTICANCER DRUGS Session PO.ET02.03 - Role of the Microenvironment in Therapeutic Response 1439 - Increasing potency of anticancer drugs through SORT1+ technology: A new targetedTHERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on specialized therapies addressing unmet medical needs in HIV, oncologyand hepatology.
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES There are many products referenced at Theratechnologies that you can find here depending on their stage of development. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691THERATECHNOLOGIES
Montreal, Canada – March 29, 2021 – Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition of two new senior resources to support the growth and development of its commercial and pipeline CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite VIRTUAL ANNUAL GENERAL MEETING GUIDELINES Virtual Annual Meeting of Shareholders, Montreal, Canada Date and Time: Thursday, May 13, 2021, at 10:00 a.m. Webcast: https://web.lumiagm.com/287439840 Download THE JOBS AVAILABLE NOW AT THERATECHNOLOGIES Position Summary. The position supports Medical Affairs in communications and coordination of internal and external events that are key to the success in Medical Affairs support for Commercial brands and Clinical development programs, and Community engagement andeducation.
MEMBERS OF THERATECHNOLOGIES MANAGEMENTTHERATECHNOLOGIES CANADATHERATECHNOLOGIES INCTHERATECHNOLOGIES NEWSTHERATECHNOLOGIESTHERF
Ms.Marie-Noël Colussi is a graduate of Université du Québec à Montréal in business administration. Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a major accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in R&D.TH1904 - THERA
TH1904. Further preclinical research activities are being conducted using TH1904, our second investigational PDC (doxorubicin conjugate). In vitro and in vivo experiments using TH1904 have demonstrated results similar to those obtained with TH1902 and support the development of additional investigational compounds using our SORT1+ Technology™ that may help in the fight against cancer. THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
THERATECHNOLOGIES
Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand
PIPELINE PRODUCTS FOUND AT THERATECHNOLOGIES Trogarzo® IV Slow Push. PHASES OF DEVELOPMENT Phase 3. EGRIFTA®. PHASES OF DEVELOPMENT Marketed. EGRIFTA SV®. PHASES OF DEVELOPMENT Marketed. NASH. Tesamorelin F8. PHASES OF DEVELOPMENT Phase 2. CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691THERATECHNOLOGIES
Montreal, Canada – March 29, 2021 – Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce the addition of two new senior resources to support the growth and development of its commercial and pipeline THE JOBS AVAILABLE NOW AT THERATECHNOLOGIES Jobs available. Send your application to cv@theratech.com. Executive Assistant. Posted on 19 May 2021. Position summary. The incumbent supports the vice presidents (Legal Affairs and Finance departments) in the success of their mandates by handling the administrative and some of the legal aspects of their functions. CHANGE TO THERATECHNOLOGIES MANAGEMENT Paul Lévesque will be appointed as President and CEO, replacing Luc Tanguay, who is retiring. Montreal, Quebec, March 2, 2020 – The board of directors of Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) is pleased to announce the appointment of Paul Lévesque as the company’s President and CEO, effective April 6, 2020, replacing Luc Tanguay, who Lire la suite VIRTUAL ANNUAL GENERAL MEETING GUIDELINES Virtual Annual Meeting of Shareholders, Montreal, Canada Date and Time: Thursday, May 13, 2021, at 10:00 a.m. Webcast: https://web.lumiagm.com/287439840 Download MEMBERS OF THERATECHNOLOGIES MANAGEMENTTHERATECHNOLOGIES CANADATHERATECHNOLOGIES INCTHERATECHNOLOGIES NEWSTHERATECHNOLOGIESTHERF
Ms.Marie-Noël Colussi is a graduate of Université du Québec à Montréal in business administration. Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a major accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in R&D.TH1904 - THERA
TH1904. Further preclinical research activities are being conducted using TH1904, our second investigational PDC (doxorubicin conjugate). In vitro and in vivo experiments using TH1904 have demonstrated results similar to those obtained with TH1902 and support the development of additional investigational compounds using our SORT1+ Technology™ that may help in the fight against cancer. THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN … 1 . THERATECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL OF TH1902 FOR SORTILIN POSITIVE SOLID TUMORS. Montreal, Canada March –24, 2012 – Theratechnologies Inc. (.Theratechnologies)
CONTACT US - THERATECHNOLOGIES Theratechnologies Address: 2015, Peel Street 11th Floor Montreal (Quebec) Canada H3A 1T8 Telephone: 514 336-7800 Fax: 514 331-9691 THE JOBS AVAILABLE NOW AT THERATECHNOLOGIES Position Summary. The position supports Medical Affairs in communications and coordination of internal and external events that are key to the success in Medical Affairs support for Commercial brands and Clinical development programs, and Community engagement andeducation.
VIRTUAL ANNUAL GENERAL MEETING GUIDELINES Virtual Annual Meeting of Shareholders, Montreal, Canada Date and Time: Thursday, May 13, 2021, at 10:00 a.m. Webcast: https://web.lumiagm.com/287439840 Download FOUNDATION AND DEVELOPMENT OF THERATECHNOLOGIES Our history. Theratechnologies was founded in 1993. Scientists at Theratechnologies discovered EGRIFTA ® (tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in peopleliving with HIV.
SCIENTIFIC CONSULTANTS WORKING WITH THERATECHNOLOGIES Dr. Grinspoon is a Professor of Medicine, Harvard Medical School, Chief of the MGH Metabolism Unit, Director of the Nutrition Obesity Research Center at Harvard and INVESTOR PRESENTATIONS FROM THERATECHNOLOGIES Here you will find investor presentations that are at the moment on our website and may be of interest to you. COMMERCIALIZED PRODUCTS Trogarzo® (ibalizumab-uiyk) injection Trogarzo ® is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. Trogarzo ® belongs to the CD4-directed post-attachment HIV-1 inhibitor class of antiretrovirals. In the United States, Trogarzo ® is approved, in combination with other AACR POSTER # 1313 #993 TH1902, A DOCETAXEL PEPTIDE-DRUG A Introduction Results (cont’d) Results (cont’d) SORT1+ Technology TMis an innovative, flexible platform consisting of novel peptides that target the sortilinreceptor (SORT1).Sortilinis preferentially expressed in cancer cells. The proprietary peptide, TH19P01, can be conjugated to well characterized anticancer agents, such as docetaxel (TH1902) and doxorubicin (TH1904), for which efficacy and THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH 1 406-01-02/18 Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1 First HIV treatment approved with a new mechanism of action in more than 10 years Infused every two weeks, only antiretroviral treatment (ART) that does not require TROGARZO® IV SLOW PUSH Currently, maintenance doses of Trogarzo® are administered by IV infusion over 15 minutes every two weeks. Maintenance doses are prepared by diluting 4 vials of Trogarzo® (800 mg in a volume of about 5.3 mL) into a 250 mL intravenous bag of 0.9% Sodium Chloride (normal saline) and then infused.NASDAQ: 3.55
TSX: 4.27
FR - EN
* About
* Our history
* Board of Directors* Leadership Team
* Scientific Consultants and Advisors* Awards
* COVID 19
* Commercialized products* Trogarzo®
* EGRIFTA®
* EGRIFTA SV®
* Product Pipeline
* Expanded Access Policy* Investors
* Overview
* Investor Presentations* News
* Financial Reports and Public Filings * Corporate Governance* Analysts
* FAQ
* Careers
* Contact
* Contact information* Email alerts
* RSS Feed
* Recherche
* FR - EN
* About
* Our history
* Board of Directors* Leadership Team
* Scientific Consultants and Advisors* Awards
* COVID 19
* Commercialized products* Trogarzo®
* EGRIFTA®
* EGRIFTA SV®
* Product Pipeline
* Expanded Access Policy* Investors
* Overview
* Investor Presentations* News
* Financial Reports and Public Filings * Corporate Governance* Analysts
* FAQ
* Careers
* Contact
* Contact information* Email alerts
* RSS Feed
* Recherche
* FR - EN
Find
HEALTH INNOVATIONS THAT MATTER Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products in the United States, Europe and Canada. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, oncologyand hepatology.
Product Pipeline
MOST RECENT
May 31, 2021
THERATECHNOLOGIES HIRES VICE PRESIDENT, HUMAN RESOURCESLearn more
May 20, 2021
DATA ON TESAMORELIN IN HIV-ASSOCIATED NAFLD FROM DR. STEVEN GRINSPOONLearn more
May 20, 2021
THERATECHNOLOGIES ANNOUNCES RESULTS FROM TWO POSTERS PRESENTED AT ACTHIV2021 ANNUAL MEETING HIGHLIGHTING POSITIVE PATIENT EXPERIENCEWITH TROGARZO®
Learn more
*
*
*
MAKING A DIFFERENCE
Theratechnologies makes a difference in the life of patients through the development and commercialization of products addressing nichetherapeutic needs.
Download the presentationOUR VALUES
AGILITY
The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in atimely manner.
TENACITY
There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving theCompany's goals.
COMMITMENT
We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company. OUR COMMERCIALIZED PRODUCTS Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is approved in the United States while EGRIFTA® is available only in Canada.Learn more
Learn more
Learn more
Learn more
Learn more
Learn more
Learn more
HIV
Trogarzo®
PHASES OF DEVELOPMENT MARKETEDTrogarzo® EU
PHASES OF DEVELOPMENT APPROVED Trogarzo® IV Slow Push PHASES OF DEVELOPMENT PHASE 3EGRIFTA®
PHASES OF DEVELOPMENT MARKETEDEGRIFTA SV®
PHASES OF DEVELOPMENT MARKETEDNASH
Tesamorelin F8
PHASES OF DEVELOPMENT PHASE 2ONCOLOGY
TH1902
PHASES OF DEVELOPMENT PHASE 1TH1904
PHASES OF DEVELOPMENT PRE-CLINICAL PHASES OF DEVELOPMENTPRE-CLINICAL
PHASE 1
PHASE 2
PHASE 3
APPROVED
MARKETED
HIV
Trogarzo®
Trogarzo® EU
Trogarzo® IV Slow PushEGRIFTA®
EGRIFTA SV®
NASH
Tesamorelin F8
ONCOLOGY
TH1902
TH1904
LATEST PRESS RELEASES Theratechnologies Hires Vice President, Human ResourcesMay 31,
2021
Theratechnologies Announces Results from Two Posters Presented at ACTHIV2021 Annual Meeting Highlighting Positive Patient Experiencewith Trogarzo®
May 20,
2021
Theratechnologies To Participate in Virtual Fireside Chat With Canaccord Genuity On May 20, 2021May 18,
2021
Announcements In Conjunction With Theratechnologies Annual MeetingMay 13,
2021
All press releases
Investors area
About
Jobs available
Investors area
About
Jobs available
Would you like to be informed about the latest releases? You will automatically receive new information by email (events, news,press releases ...)
Configure my alerts
* About
* Commercialized products* Product Pipeline
* Investors
* Careers
* Contact
-------------------------Email alerts
RSS
©2019 - Theratechnologies Inc.Terms of use
Privacy
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0